Intelligence Unit
Special Reports
Special Events
Subscribe
Sponsored
Departments
- Leadership
- Finance
- Technology
- Physicians
- Community Hospitals
- Health Plans
- Marketing
- Quality
- Nursing
- HR
Follow Us
Data may help cancer drug gain approval for wider use
Wall Street Journal (subscription required), December 11, 2007
Clinical-trial results showing that the blood-cancer drug Velcade increases remission rates in patients could boost its chances of winning regulatory approval for wider use. Velcade currently is approved in the United States to treat multiple myeloma in patients who have received at least one prior therapy.
Most Viewed
Most Emailed
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- How Chargemaster Data May Affect Hospital Revenue
- House Lawmakers Grill CMS Over Health Exchange Navigators
- Fortunately, Angelina Jolie Isn't On Medicare
- ED Physicians Key to Half of Hospital Admissions
- Primary Care Docs Average More Hospital Revenue Than Specialists
- Don't Let Nurses Sink Your Bottom Line
- Insurer's App Aims to Lower Healthcare Costs, Securely
- Uncompensated Care Faces a Double Hit in Some States
- 69% of Employers Plan to Offer Healthcare Coverage After 2014
